NCT06716008

Brief Summary

Evaluate the effect of manual diaphragmatic release on ventilatory functions in women with rheumatoid arthritis

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 29, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

December 3, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 4, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2025

Completed
22 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

December 9, 2024

Status Verified

December 1, 2024

Enrollment Period

3 months

First QC Date

November 29, 2024

Last Update Submit

December 4, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Ventilatory function

    Ventilatory function parameters, including forced vital capacity and forced expiratory volume in the first second will be measured by experienced technicians at baseline and after 12 weeks in all groups using the Medgraphics pulmonary function testing system (Breezesuite Ultima PFX, Milano, Italy) in strict adherence to the guidelines outlined in the user manual.

    At baseline and 12 weeks

Secondary Outcomes (1)

  • Functional capacity

    At baseline and after 12 weeks

Study Arms (2)

Manual diaphragmatic release group

ACTIVE COMPARATOR

30 women with rheumatoid arthritis who will receive low to moderate intensity aerobic training plus manual diaphragmatic release

Other: Aerobic trainingOther: Manual Diaphragm Release

Control group

ACTIVE COMPARATOR

30 women with rheumatoid arthritis who will receive low to moderate intensity aerobic training only.

Other: Aerobic training

Interventions

For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.

Control groupManual diaphragmatic release group

The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.

Manual diaphragmatic release group

Eligibility Criteria

Age40 Years - 60 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemales
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • All women will have rheumatoid arthritis for more than 2 years with low-to-moderate disease activity.
  • Normal to mildly restrictive lung pattern.
  • Their ages will be ranged from 40 to 60 years old.
  • Their body mass index will be less than 30 Kg/m2.

You may not qualify if:

  • Chronic chest diseases.
  • Recent parenteral steroid administration.
  • Cardiovascular disorders (coronary heart disease, heart failure, cardiac arrhythmia, peripheral arterial disease, uncontrolled hypertension).
  • Smokers.
  • Joint surgery (in the preceding 6 months).
  • Musculoskeletal/ neurological limitations to exercise.
  • Pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Rheumatic Fever

Condition Hierarchy (Ancestors)

Streptococcal InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Mohammed Sayed Saif, Ph.D

    National institute for Gerontology

    STUDY DIRECTOR

Central Study Contacts

Saher Elgayar, Ph.D

CONTACT

Mohammed Sayed Saif, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Physical Therapy

Study Record Dates

First Submitted

November 29, 2024

First Posted

December 4, 2024

Study Start

December 3, 2024

Primary Completion

March 10, 2025

Study Completion

April 1, 2025

Last Updated

December 9, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share